Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Current Assets (2019 - 2025)

Biodesix (BDSX) has disclosed Current Assets for 7 consecutive years, with $32.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets fell 17.64% year-over-year to $32.5 million, compared with a TTM value of $32.5 million through Dec 2025, down 17.64%, and an annual FY2025 reading of $32.5 million, down 17.64% over the prior year.
  • Current Assets was $32.5 million for Q4 2025 at Biodesix, down from $33.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $81.2 million in Q1 2021 and bottomed at $24.1 million in Q3 2022.
  • Average Current Assets over 5 years is $40.8 million, with a median of $34.9 million recorded in 2022.
  • The sharpest move saw Current Assets surged 211.01% in 2021, then tumbled 66.48% in 2022.
  • Year by year, Current Assets stood at $43.6 million in 2021, then rose by 22.29% to $53.3 million in 2022, then dropped by 25.6% to $39.7 million in 2023, then decreased by 0.5% to $39.5 million in 2024, then dropped by 17.64% to $32.5 million in 2025.
  • Business Quant data shows Current Assets for BDSX at $32.5 million in Q4 2025, $33.4 million in Q3 2025, and $32.4 million in Q2 2025.